316 related articles for article (PubMed ID: 19332720)
1. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
3. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Sorensen AG; Batchelor TT; Zhang WT; Chen PJ; Yeo P; Wang M; Jennings D; Wen PY; Lahdenranta J; Ancukiewicz M; di Tomaso E; Duda DG; Jain RK
Cancer Res; 2009 Jul; 69(13):5296-300. PubMed ID: 19549889
[TBL] [Abstract][Full Text] [Related]
4. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
Momeny M; Shamsaiegahkani S; Kashani B; Hamzehlou S; Esmaeili F; Yousefi H; Irani S; Mousavi SA; Ghaffari SH
Life Sci; 2021 Dec; 287():120100. PubMed ID: 34715143
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
7. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
[TBL] [Abstract][Full Text] [Related]
8. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Batchelor TT; Sorensen AG; di Tomaso E; Zhang WT; Duda DG; Cohen KS; Kozak KR; Cahill DP; Chen PJ; Zhu M; Ancukiewicz M; Mrugala MM; Plotkin S; Drappatz J; Louis DN; Ivy P; Scadden DT; Benner T; Loeffler JS; Wen PY; Jain RK
Cancer Cell; 2007 Jan; 11(1):83-95. PubMed ID: 17222792
[TBL] [Abstract][Full Text] [Related]
9. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
[TBL] [Abstract][Full Text] [Related]
10. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
Dietrich J; Wang D; Batchelor TT
Expert Opin Investig Drugs; 2009 Oct; 18(10):1549-57. PubMed ID: 19671039
[TBL] [Abstract][Full Text] [Related]
11. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.
Gerstner ER; Chen PJ; Wen PY; Jain RK; Batchelor TT; Sorensen G
Neuro Oncol; 2010 May; 12(5):466-72. PubMed ID: 20406897
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Farrar CT; Kamoun WS; Ley CD; Kim YR; Catana C; Kwon SJ; Rosen BR; Jain RK; Sorensen AG
PLoS One; 2011 Mar; 6(3):e17228. PubMed ID: 21390238
[TBL] [Abstract][Full Text] [Related]
13. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
14. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Batchelor TT; Gerstner ER; Emblem KE; Duda DG; Kalpathy-Cramer J; Snuderl M; Ancukiewicz M; Polaskova P; Pinho MC; Jennings D; Plotkin SR; Chi AS; Eichler AF; Dietrich J; Hochberg FH; Lu-Emerson C; Iafrate AJ; Ivy SP; Rosen BR; Loeffler JS; Wen PY; Sorensen AG; Jain RK
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19059-64. PubMed ID: 24190997
[TBL] [Abstract][Full Text] [Related]
15. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
Siemann DW; Brazelle WD; Jürgensmeier JM
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):897-903. PubMed ID: 19215823
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
di Tomaso E; Snuderl M; Kamoun WS; Duda DG; Auluck PK; Fazlollahi L; Andronesi OC; Frosch MP; Wen PY; Plotkin SR; Hedley-Whyte ET; Sorensen AG; Batchelor TT; Jain RK
Cancer Res; 2011 Jan; 71(1):19-28. PubMed ID: 21199795
[TBL] [Abstract][Full Text] [Related]
17. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Sorensen AG; Emblem KE; Polaskova P; Jennings D; Kim H; Ancukiewicz M; Wang M; Wen PY; Ivy P; Batchelor TT; Jain RK
Cancer Res; 2012 Jan; 72(2):402-7. PubMed ID: 22127927
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
19. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Momeny M; Sankanian G; Hamzehlou S; Yousefi H; Esmaeili F; Alishahi Z; Karimi B; Zandi Z; Shamsaiegahkani S; Sabourinejad Z; Kashani B; Nasrollahzadeh A; Mousavipak SH; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2020 Sep; 882():173298. PubMed ID: 32593665
[TBL] [Abstract][Full Text] [Related]
20. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Morton CL; Maris JM; Keir ST; Gorlick R; Kolb EA; Billups CA; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2012 Apr; 58(4):566-71. PubMed ID: 21538824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
